Several other analysts have also recently commented on the stock. Analysts at Stephens upgraded shares of Haemonetics from an “equal weight” rating to an “overweight” rating in a research note to investors on Tuesday, May 1st. Separately, analysts at Morgan Stanley (NYSE: MS) upgraded shares of Haemonetics from an “underweight” rating to an “equal weight” rating in a research note to investors on Tuesday, May 1st. They now have a $55.00 price target on the stock. Finally, analysts at Raymond James (NYSE: RJF) initiated coverage on shares of Haemonetics in a research note to investors on Wednesday, April 25th. They set a “market perform” rating on the stock.
Haemonetics traded down 0.10% on Wednesday, hitting $69.54. Haemonetics has a 52-week low of $54.99 and a 52-week high of $71.50. The company has a market cap of $1.762 billion and a price-to-earnings ratio of 26.88.
Haemonetics last announced its earnings results on Monday, April 30th. The company reported $0.80 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.83 by $0.03. Haemonetics’s revenue was up 9.8% compared to the same quarter last year. On average, analysts predict that Haemonetics will post $0.80 earnings per share next quarter.
Haemonetics Corporation is a medical device company. It is engaged in developing and manufacturing automated blood component collection devices and surgical blood salvage devices.